Which Stent Type is Best for Patients with Diabetes?

Three-year findings from a registry study suggest that DES are more effective than BMS are.

In this study, investigators used data from a Massachusetts state registry that mandates reporting and follow-up of all percutaneous coronary interventional procedures to compare 3-year outcomes after drug-eluting stent (DES) implantation with those after bare-metal stent (BMS) implantation in patients with diabetes. Because patients were not randomized to stent types, the investigators used propensity matching to adjust for between-group differences in baseline and procedural characteristics.

The study population included patients with diabetes (one third of whom required insulin) who received stents from April 2003 to October 2004 (29% of all stent recipients during this time). Of the diabetic patients, 3341 received DES (73% sirolimus-elu…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)